Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
Background Fostemsavir [FTR] is approved for use with other active antiretrovirals [ARVs] for treatment of heavily treatment-experienced people with HIV [PWH] and multi-drug resistance [MDR]. We described characteristics and treatment outcomes among PWH prescribed FTR in a real-world setting in the US. Methods PWH initiating FTR from July 2020 (FDA approval) to June 2023 identified…
Background Sustained expression of adeno-associated virus (AAV)-vectored anti-HIV-1 broadly neutralizing antibodies (bNAbs) could prevent and treat HIV-1 infection. However, durable expression of AAV-vectored bNAbs in vivo is limited by host immune responses, impeding efficacy studies in preclinical nonhuman primate (NHP) models. Programmed cell death protein (PD)-1 is an immune checkpoint protein on T cells that…
Background Ensitrelvir, an oral main protease inhibitor targeting SARS-CoV-2, demonstrated robust antiviral activity in the phase 3 SCORPIO-HR/ACTIV-2d trial with a significant reduction in viral RNA levels and a higher percentage of negative viral cultures at Day 4 compared to placebo. In this exploratory analysis, we investigated emergence of resistance-associated mutations with ensitrelvir treatment. Methods…
Background Nirmatrelvir/ritonavir (N/r) is approved for the outpatient treatment of COVID-19 within 5 days of symptom onset and is typically used in patients at increased risk for severe disease. In severely immunocompromised patients, COVID-19 occasionally evolves into a chronic infection. The potential value of N/r in this context including optimal treatment duration is unknown. We…
Background Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) is a simple highly potent antiretroviral (ART) regimen with a high genetic barrier to resistance. However, real-world evidence in the presence of drug resistance mutations (DRMs) remains limited. We investigated virological factors associated to virological failure (VF) after switching to B/F/TAF in individuals with pre-existing DRMs. Methods We performed a retrospective…
Background DTG/3TC and BIC/FTC/TAF are recommended ART regimens in major HIV guidelines. However, data on the metabolic and inflammatory effects of switching from DTG/3TC to BIC/FTC/TAF are scarce. We investigated the impact of this switch on metabolic parameters and systemic inflammation in virologically suppressed individuals. Methods This randomized, open-label, multicenter INSTINCT study (GESIDA10918) assessed the…
Background Women represent ~20% of people with HIV in the US and may experience unique challenges with HIV treatment. Cabotegravir + rilpivirine long-acting (CAB+RPV LA) injectable, indicated for treatment experienced individuals with viral loads (VL) <50 copies/mL, is the first complete LA antiretroviral regimen approved for HIV-1 treatment. This study assessed clinical outcomes among virologically…
Background LA CAB/RPV has transformed the HIV treatment paradigm as an alternative to daily oral antiretroviral therapy (ART). Potential challenges with CAB/RPV include therapeutic failures characterized by virologic failure and/or the development of resistance-associated mutations (RAMs). Methods This was a single-center, retrospective cohort study of adults with HIV on LA CAB/RPV at the Ohio State…
Background Immunocompromised patients who are hospitalized with COVID-19 and initiate remdesivir (RDV) within the first 2 days of hospitalization have a lower risk of all-cause mortality than those who do not initiate RDV. However, it is unknown what proportions of patients with immunocompromising conditions (when stratified by age or the SARS-CoV-2 variant period) initiate RDV…
Background Residual immune activation/inflammation is a hallmark of treated HIV. Dual (2DR) regimens are efficacious in maintaining viral suppression, however, their effect on T-cell homeostasis and mitochondrial damage, is ill-defined. Methods PLWH switching from viro-suppressive, three drug (3DR) cART to an INSTI-based 2DR with sample availability (at switch and approximately 12 months from switch) were…